The role of Fas in the progression of ischemic heart failure: Prohypertrophy or proapoptosis

Coronary Artery Disease

Volumn 19, Issue 7, 2008, Pages 527-534

  Feng, Quan Zhou ^a   Zhao, Yu Sheng ^a   Abdelwahid, Eltyeb ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Apoptosis; Fas; Heart failure; Hypertrophy; Myocardial ischemia infarction

Indexed keywords

FAS ANTIGEN;

APOPTOSIS; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; HYPERTROPHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; UPREGULATION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CARDIOMEGALY; DISEASE PROGRESSION; FAS LIGAND PROTEIN; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION;

EID: 55749099178     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283093707     Document Type: Review

References (62)

1. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, et al. On behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992; 327:669-677.
2. Pfeffer JM, Reffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 1991; 260:H1406-H1414.
3. Takemura G, Fujiwara H. Role of apoptosis in remodeling after myocardial infarction. Pharmacol Ther 2004; 104:1-16.
4. Murtuza B, Suzuki K, Bou-Gharios G, Beauchamp JR, Smolenski RT, Partridge TA, et al. Transplantation of skeletal myoblasts secreting an IL-1 inhibitor modulates adverse remodeling in infarcted murine myocardium. Proc Natl Acad Sci U S A 2004; 101:4216-4221.
5. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
6. Wollert KC, Heineke J, Westermann J, Ludde M, Fiedler B, Zierhut W, et al. The cardiac Fas (APO-1/CD95) receptor/Fas ligand system: relation to diastolic wall stress in volume-overload hypertrophy in vivo and activation of the transcription factor AP-1 in cardiac myocytes. Circulation 2000; 101:1172-1178.
7. Badorff C, Ruetten H, Mueller S, Stahmer M, Gehring D, Jung F, et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest 2002; 109:373-381.
8. Jeremias I, Kupatt C, Martin-Villalba A, Habazettl H, Schenkel J, Boekstegers P, et al. Involvement of CD95/Apo1/Fas in cell death after myocardial ischemia. Circulation 2000; 102:915-920.
9. Setsuta K, Seino Y, Ogawa T, Ohtsuka T, Seimiya K, Takano T. Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system. Circ J 2004; 68:747-750.
10. Huang Y, Hunyor SN, Jiang L, Kawaguchi O, Shirota K, Ikeda Y, et al. Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural, and cellular responses. Am J Physiol Heart Circ Physiol 2004; 286:H2141-H2150.
11. Rho MC, Kim YK, Chang JS, Lee HS, Baek JA, Chung MY, et al. 7-Ketocholesterol predisposes human aorta smooth muscle cells to Fas-mediated death. J Mol Cell Cardiol 2005; 39:823-832.
12. Smyth LA, Brady HJ. cMet and Fas receptor interaction inhibits death-inducing signaling complex formation in endothelial cells. Hypertension 2005; 46:100-106.
13. Afanasyeva M, Georgakopoulos D, Belardi DF, Bedja D, Fairweather D, Wang Y, et al. Impaired up-regulation of CD25 on CD4+ T cells in IFN-gamma knockout mice is associated with progression of myocarditis to heart failure. Proc Natl Acad Sci U S A 2005; 102:180-185.
14. Niu J, Azfer A, Deucher MF, Goldschmidt-Clermont PJ, Kolattukudy PE. Targeted cardiac expression of soluble Fas prevents the development of heart failure in mice with cardiac-specific expression of MCP-1. J Mol Cell Cardiol 2006; 40:810-820.
15. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J Biol Chem 1992; 267:10709-10715.
16. MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002; 14:477-492.
17. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:1169-1178.
18. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305-1308.
19. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002; 296:1635-1636.
20. Sharp DA, Lawrence DA, Ashkenazi A. Selective knockdown of the long variant of cellular FLICE-inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 2005; 280:19401-19409.
21. Budd RC. Death receptors couple to both cell proliferation and apoptosis. J Clin Invest 2002; 109:437-441.
22. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148:1274-1279.
23. Feng OZ, LJ TD, Wei LX, Qiao X, Yi J, Wang L, et al. Tempera-spatial dissociation between the expression of Fas and apoptosis after coronary occlusion. Mol Pathol 2003; 56:362-367.
24. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, Koh E. Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: In vivo study. Circulation 2000; 102:572-578.
25. Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, et al. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res 1994; 75:426-433.
26. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996; 74:86-107.
27. Yaniv G, Shilkrut M, Lotan R, Berke G, Larisch S, Binah O. Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the Fas (CD95/Apo-1) receptor: Fas activation and apoptosis in hypoxic myocytes. Cardiovasc Res 2002; 54:611-623.
28. Stephanou A, Scarabelli TM, Brar BK, Nakanishi Y, Matsumura M, Knight RA, et al. Induction of apoptosis and Fas receptor/Fas ligand expression by ischemia/reperfusion in cardiac myocytes requires serine 727 of the STAT-1 transcription factor but not tyrosine 701. J Biol Chem 2001; 276:28340-28347.
29. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffet GE, Peschon JJ, Sivasubramanian N, et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A 2000; 97:5456-5461.
30. Nediani C, Celli A, Formigli L, Perna AM, Fiorillo C, Ponziani V, et al. Possible role of acylphosphatase, Bcl-2 and Fas/Fas-L system in the early changes of cardiac remodeling induced by volume overload. Biochim Biophys Acta 2003; 1638:217-226.
31. Filippatos G, Leche C, Sunga R, Tsoukas A, Anthopoulos P, Joshi I, et al. Expression of FAS adjacent to fibrotic foci in the failing human heart is not associated with increased apoptosis. Am J Physiol 1999; 277: H445-H451.
32. Ohno M, Takemura G, Ohno A, Misao J, Hayakawa Y, Minatoguchi S, et al. 'Apoptotic' myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis by immunogold electron microscopy combined with In situ nick end-labeling. Circulation 1998; 98:1422-1430.
33. Kanoh M, Takemura G, Misao J, Hayakawa Y, Aoyama T, Nishigaki K, et al. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy: not apoptosis but DNA repair. Circulation 1999; 99:2757-2764.
34. Yamaoka M, Yamaguchi S, Suzuki T, Okuyama M, Nitobe J, Nakamura N, et al. Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. J Mol Cell Cardiol 2000; 32:881-889.
35. Lee P, Sata M, Lefer DJ, Factor SM, Walsh K, Kitsis RN. Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo. Am J Physiol Heart Circ Physiol 2003; 284:H456-H463.
36. Hayakawa K, Takemura G, Koda M, Kawase Y, Maruyama R, LJ Y, et al. Sensitivity to apoptosis signal, clearance rate, and ultrastructure of fas ligand-induced apoptosis in in vivo adult cardiac cells. Circulation 2002; 105:3039-3045.
37. Tekin D, Xi L, Kukreja RC. Genetic deletion of fas receptors or Fas ligands does not reduce infarct size after acute global ischernia-reperfusion in isolated mouse heart. Cell Biochem Biophys 2006; 44:111-117.
38. Gomez L, Chavanis N, Argaud L, Chalabreysse L, Gateau-Roesch O, Ninet J, et at. Fas-independent mitochondrial damage triggers cardiomyocyte death after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2005; 289:H2153-H2158.
39. Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997; 185:1481-1486.
40. Crow MT, Mani K, Nam YJ, Kitsis RN. The mrtochondrial death pathway and cardiac myocyte apoptosis. Circ Res 2004; 95:957-970.
41. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489.
42. Borutaite V, Budriunaite A, Morkuniene R, Brown GC. Release of mitochondrial cytochrome c and activation of cytosolic caspases induced by myocardial ischaemia Biochim Biophys Acta 2001; 1537:101-109.
43. Bialik S, Cryns VL, Drincic A, Miyata S, Wollowick AL, Srinivasan A, et al. The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res 1999; 85:403-414.
44. Kumar D, Lou H, Singal PK. Oxidative stress and apoptosis in heart dysfunction. Herz 2002; 27:662-668.
45. Byrne JA, Grieve DJ, Cave AC, Shah AM. Oxidative stress and heart failure. Arch Mal Coeur Vaiss 2003; 96:214-221.
46. Qin F, Patel R, Van C, Liu W. NADPH oxidase is involved in angiotensin II-induced apoptosis in H9C2 cardiac muscle cells: effects of apocynin. Free Radical Biol Med 2006; 40:236-246.
47. Takemura Y, Fukuo K, Yasuda O, Inoue T, lnomata N, Yokoi T, et al. Fas signaling induces Akt activation and upregulation of endothelial nitric oxide synthase expression. Hypertension 2004; 43:880-884.
48. Kang PM, Yue P, Liu Z, Inoue T, Inomata N, Yokoi T. Alterations in apoptosis regulatory factors during hypertrophy and heart failure. Am J Physiol Heart Circ Physiol 2004; 287:H72-H80.
49. Sam F, Sawyer DB, Chang DL, Eberli FR, Ngoy S, Jain M, et al. Progressive left ventricular remodeling and apoptosis late after myocardial infarction in mouse heart. Am J Physiol Heart Circ Physiol 2000; 279:H422-H428.
50. Anversa P, Olivetti G, Leri A, Liu Y, Kajstura J. Myocyte cell death and ventricular remodeling. Curr Opin Nephrol Hypertens 1997; 6:169-176.
51. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003; 285:H1229-H1235.
52. Cheng W, Kajstura J, Nitahara JA, Li B, Reise K, Liu Y, et al. Programmed myocyte cell death affects the viable myocardium after infarction in rats. Exp Cell Res 1996; 226:316-327.
53. Sharov VG, Sabbah HN, Shimoyama H, Goussev AV, Lesch M, Goldstein S. Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 1996; 148:141-149.
54. Chen OM, Tu VC. Apoptosis and heart failure: mechanisms and therapeutic implications. Am J Cardiovasc Drugs 2002; 2:43-57.
55. Abbate A, Biondi-Zoccai G, Petrolini A, Biasucci LM, Baldi A. Clinical relevance of apoptosis in early and late post-infarction left ventricular remodeling, Ital Heart J 2002; 3:699-705.
56. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N. Relation between circulating soluble Fas ligand and subsequent ventricular remodelling following myocardial infarction. Heart 2003; 89:339-341.
57. Zhu YZ, Zhu YC, Wang ZJ, Lu Q, Lee HS, Unger T. Time-dependent apoptotic development and pro-apoptotic genes expression in rat heart after myocardial infarction. Jpn J Pharmacol 2001; 86:355-358.
58. Olivetti G, Quaini F, Sala R, Lagrasta C, Corradi D, Bonacina E, et al. Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart. J Mol Cell Cardiol 1996; 28:2005-2016.
59. Parissis JT, Adamopoulos S, Antoniades C, Kostakts G, Rigas A, Kyrzopoutos S, et al. Effects of tevosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004; 93:1309-1312.
60. Kanamori H, Takemura G, Li Y, Okada H, Maruyama R Aoyama T, et al. Inhibition of Fas-associated apoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricular remodeling by olmesartan. Am J Physiol Heart Circ Physiol 2007; 292: H2184-H2194.
61. Li Y, Takemura G, Kosai K, Takahashi T, Okada H, Miyata S, et al. Critical roles for the Fas/Fas ligand system in postinfarction ventricular remodeling and heart failure. Circ Res 2004; 95:627-636.
62. Sano M, Wang SC, Shirai M, Scaglia F, Xie M, Sakai S, et al. Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO J 2004; 23:3559-3569.